NeuroSpectrum Insights, which is developing a medical device for diagnosing neurological and neurodevelopmental disorders, filed on Friday with the SEC to raise up to $15 million in an initial public offering.
NeuroSpectrum Insights is a medical device company developing computerized analysis technology that enhances clinicians' capabilities in diagnosing neurological and neurodevelopmental disorders. The company's first product, GyriCalc, is a proprietary, patented software solution specifically designed to assist in the diagnosis of autism by identifying early structural markers of neurodevelopmental differences through the automated analysis of MRI images. NeuroSpectrum Insights has not generated any revenues to date.
The Bedminster, NJ-based company was founded in 2016 and plans to list on the NYSE but has not selected a symbol yet (RC ticker: NSI.RC). NeuroSpectrum Insights filed confidentially on October 28, 2024. Network 1 Financial Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
